Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM15912 in Short Bowel Syndrome-associated Intestinal Failure
NCT04775706Phase 2Recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2022
- Primary completion
- Dec 2027
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in short bowel syndrome (SBS) comparing HM15912 Active with Placebo (2 arms). Primary endpoint: Incidence of adverse events at 24 weeks. Started Mar 2022; status: recruiting.
02
Drugs
sonefpeglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04775706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775706.